Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Forest Laboratories



) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 2.0%. By the end of trading, Forest Laboratories fell $1.15 (-1.2%) to $91.30 on light volume. Throughout the day, 1,614,667 shares of Forest Laboratories exchanged hands as compared to its average daily volume of 3,856,700 shares. The stock ranged in price between $91.29-$93.67 after having opened the day at $92.69 as compared to the previous trading day's close of $92.45. Other companies within the Health Care sector that declined today were:




), down 39.4%,




), down 19.3%,

Aastrom Biosciences



), down 15.2% and




), down 13.1%.

Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products in the United States and Europe. Forest Laboratories has a market cap of $25.1 billion and is part of the drugs industry. Shares are up 54.0% year to date as of the close of trading on Tuesday. Currently there are 9 analysts that rate Forest Laboratories a buy, no analysts rate it a sell, and 14 rate it a hold.

TheStreet Ratings rates

Forest Laboratories

as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, good cash flow from operations and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front,

Keryx Biopharmaceuticals



), up 17.4%,




), up 12.6%,

Fate Therapeutics



), up 11.6% and

Conatus Pharmaceuticals



), up 6.2% , were all gainers within the health care sector with

Laboratory Corporation of America Holdings



) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR



) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care




STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.